← Mechanisms of action
unidentified adenovirus
ORGANISMunidentified adenovirus
Drugs acting on this target (12)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| brincidofovir (Tembexa) | Antagonist | approved | Small molecule | unidentified adenovirus antagonist |
| ad4-envc150 | Immunity, active | experimental | Vaccine | unidentified adenovirus immunity, active |
| ad4/ad7 vaccine | Immunity, active | experimental | Vaccine | unidentified adenovirus immunity, active |
| pxvx0047 | Immunity, active | experimental | Vaccine | unidentified adenovirus immunity, active |
| type-4 adv vaccine | Immunity, active | experimental | Vaccine | unidentified adenovirus immunity, active |
| type-7 adv vaccine | Immunity, active | experimental | Vaccine | unidentified adenovirus immunity, active |
| adenovirus-specific t-cells | Immunity, passive | experimental | Cell therapy | unidentified adenovirus immunity, passive |
| cmv/adv specific t cells | Immunity, passive | experimental | Cell therapy | unidentified adenovirus immunity, passive |
| ifn-gamma-secreting hadv antigen specific t cells | Immunity, passive | experimental | Cell therapy | unidentified adenovirus immunity, passive |
| ifnγ- positive selected t-cells | Immunity, passive | experimental | Cell therapy | unidentified adenovirus immunity, passive |
| Posoleucel (viralym-a) | Immunity, passive | experimental | Cell therapy | unidentified adenovirus immunity, passive |
| virus-specific T cells | Immunity, passive | experimental | Cell therapy | unidentified adenovirus immunity, passive |